Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency

Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening complication in patients with CVID, but the optimal treatment is unknown.

Source: Journal of Allergy and Clinical Immunology - July 30, 2020 Category: Allergy & Immunology Authors: James W. Verbsky, Mary K. Hintermeyer, Pippa M. Simpson, Mingen Feng, Jody Barbeau, Nagarjun Rao, Carlyne D. Cool, Luis A. Sosa-Lozano, Dhiraj Baruah, Erin Hammelev, Alyssa Busalacchi, Amy Rymaszewski, Jeff Woodliff, Shaoying Chen, Mary Bausch-Jurken, Joh Source Type: research